Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27704388 | 1.00 | CASP3 (0.59) | CASP3KMT2AMDM4TP53PIN1 | |
| SCHEMBL5056975 | 1.00 | CASP3 (0.59) | CASP3KMT2AMDM4TP53PIN1 | |
| SCHEMBL30355270 | 1.00 | CASP3 (0.59) | CASP3KMT2AMDM4TP53PIN1 | |
| SCHEMBL30896048 | 0.89 | CASP3 (0.52) | CASP3KMT2AMDM4TP53PIN1 | |
| SCHEMBL1486287 | 0.89 | CASP3 (0.52) | CASP3KMT2AMDM4TP53PIN1 | |
| SCHEMBL118209 | 0.89 | CASP3 (0.52) | CASP3KMT2AMDM4TP53PIN1 | |
| SCHEMBL1564185 | 0.89 | CASP3 (0.52) | CASP3KMT2AMDM4TP53PIN1 | |
| SCHEMBL119497 | 0.89 | CASP3 (0.52) | CASP3KMT2AMDM4TP53PIN1 | |
| SCHEMBL30896049 | 0.89 | CASP3 (0.52) | CASP3KMT2AMDM4TP53PIN1 | |
| SCHEMBL6038102 | 0.89 | CASP3 (0.52) | CASP3KMT2AMDM4TP53PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101189253-A | Antiinfective lipopeptides | CUBIST PHARM INC (US) | 2008-05-28 | — | — | CN | disclosed |
| US-20080051326-A1 | Antiinfective Lipopeptides | CUBIST PHARMACEUTICALS, INC. | 2008-02-28 | — | — | US | disclosed |
| EP-1814588-A2 | ANTIINFECTIVE LIPOPEPTIDES | Cubist Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006110185-A2 | ANTIINFECTIVE LIPOPEPTIDES | CUBIST PHARMACEUTICALS, INC. (US) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051326-A1 | Antiinfective Lipopeptides | VIP, NGLY1, PREP | CASP3 1022/4885KMT2A 4448/4885MDM4 1783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.